Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2024 / Nov / Also in the News… (3)
Research & Innovations Anterior Segment Cataract Anterior Segment Cornea

Also in the News…

From the “Female Executive of the Year” to disparities in retinoblastoma care, these are the news stories and studies that caught our attention this week…

By Alun Evans 11/22/2024 1 min read

Share

Eneas de Troya  and Olga Cadena, CC BY 2.0 https://creativecommons.org/licenses/by/2.0, via Wikimedia Commons

Dry eye results. Sun Pharma’s approved dry eye treatment, CEQUA, has shown significant improvements in total corneal staining and visual acuity for phase IV participants in a 12-week study period. The results were presented by Brandon Ayres at this year’s American Academy of Ophthalmology (AAO) event. Link

Ciliatech advisory board. Ciliatech, a medtech company specializing in ophthalmology, has established a new key opinion leader (KOL) advisory board. The seven-member board will help bring the Intercil Uveal Spacer – the company’s new cilioscleral inter-positioning device (CID) for glaucoma – to market. Link

Female exec of the year. CooperVision’s Vice President of Marketing and Professional Affairs for the Americas, Michele Andrews, has been awarded a gold Stevie award and named Female Executive of the Year in the award’s Women in Business category. The Stevie awards were created in 2002 to honor the achievements and contributions of women in business worldwide. Link

Air pollution and cataract surgery links. Researchers investigating the relationship between air pollution and cataract incidence have indicated that long-term nitrogen dioxide exposure can lead to an almost 50 percent increase in the risk of an individual developing cataracts. The study, published in Acta Ophthalmologica and conducted by a team based at the Universitaire de Bordeaux, France, and the University of Basel, Switzerland, suggests that countries who comply with currency European air pollution standards could help reduce cataract surgery costs, while improving their population’s overall quality of life. Link

Retinoblastoma disparities. Despite an overall decline in cases of enucleation across the country, a study conducted by Stanford University School of Medicine and the University of California has found that retinoblastoma enucleations are still prevalent among the Hispanic and rural populations of the US. The authors say their findings highlight unequal access to care (and to globe-sparing treatments like local tumor destruction and chemotherapy) in the population; they call for further studies to investigate the disparity. Link

Opthea wet AMD program. Gregg T. Kokame will present data from a predefined subgroup of the sozinibercept phase IIb wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV) in a rapid fire session at this week’s Asia-Pacific Vitreo-Retina Society Congress (APVRS, November 22-24) in Singapore. Link

Neuroprotective effects of growth hormone. A new study has explored the neuroprotective potential of growth hormone (GH) in preserving retinal ganglion cells (RGCs) and optic nerve integrity after optic nerve crush (ONC) in male rats. The results – highlighted by the Universidad Nacional Autónoma de México and the Universidad Autónoma de Aguascalientes, Mexico – demonstrate that GH administration can reduce RGC death, limit gliosis, improve axonal transport, and maintain retinal function, possibly by regulating antiapoptotic proteins, neurotrophic factors, and glial activity. The findings suggest that GH has potential as a therapeutic approach for retinal neurodegenerative diseases. Link

About the Author(s)

Alun Evans

More Articles by Alun Evans

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: